Abstracts tagged "Disease Activity"

Abstract Number: 1293 • ACR Convergence 2024
Educational Quality Improvement (QI) Project to Improve Inpatient Purine Restricted Diet Order Placement for Patients Admitted with Gout Flares
OKEOGHENE AKPOIGBE¹, COMFORT ANIM-KORANTENG², BETTINA ESCOLANO³, NI NI LWIN¹, JOANNA PANGILINAN¹ and Amanda Sammut⁴, ¹New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, NY, ²New York City Health and Hospitals/Harlem in Affliation with Columbia University, Bronx, NY, ³New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, ⁴New York City Health and Hospitals/Harlem. Rheumatology Department, Chappaqua, NY
Background/Purpose: Gout is a chronic, but treatable, inflammatory disease characterized by intermittent flares involving the deposition of monosodium urate crystals in and around joints. It…
Abstract Number: 1367 • ACR Convergence 2024
Maintained Improvement of Disease Activity and Patient-reported Outcomes (PROs) with Filgotinib in Patients with Rheumatoid Arthritis (RA) in the Real World: Up to 2-year Interim Data from FILOSOPHY
James Galloway¹, Jérôme Avouac², Gerd Burmester³, Roberto Caporali⁴, Thomas P.A. Debray⁵, Katrien Van Beneden⁶, Neil Betteridge⁷, Susana Romero Yuste⁸, Monia Zignani⁵, Patrick Verschueren⁹ and Karen Bevers¹⁰, ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ³Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁴Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁵Alfasigma S.p.A., Bologna, Italy, ⁶Medical Affairs, Galapagos NV, Mechelen, Belgium, ⁷Neil Betteridge Associates, Lonodn, United Kingdom, ⁸Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, ⁹Department of Rheumatology, University Hospital Leuven and KU Leuven, Leuven, Belgium, ¹⁰Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: FILOSOPHY (NCT04871919) and PARROTFISH (NCT05323591) are ongoing, prospective, observational Phase 4 studies of filgotinib in patients with RA. This interim analysis evaluated effectiveness and…
Abstract Number: 1519 • ACR Convergence 2024
Incidence, Risk Factors, and Outcomes of Severe Lymphopenia in Systemic Lupus Erythematosus
Chunhui Chen¹, Emily Wu², Huong Do³ and Kyriakos Kirou³, ¹New York Presbyterian Queens, Flushing, NY, ²Hospital for Special Surgery, Rochester, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: Lymphopenia is common in patients with systemic lupus erythematosus (SLE), occurring in 75-90% of cases over the disease course. It can result from SLE…
Abstract Number: 1875 • ACR Convergence 2024
Assessing the PULSAR (Program to Understand the Longterm Outcomes in Spondyloarthritis) Registry for Environmental Determinants of Heath Research
Liya Stolyar¹, Diane Mar², Yuhan Liu³, Esther Velasquez⁴, orr Sharpe⁵, Michael Weisman⁶, Liron Caplan⁷ and suzanne Tamang⁸, ¹Palo Alto VA Medical Center/Stanford, Stanford, CA, ²Palo Alto VA Medical Center/Stanford University Medical Center, Palo Alto, CA, ³Stanford Medicine Quantitative Sciences Unit, Palo Alto, CA, ⁴Stanford Center for Population Health Sciences, Palo Alto, CA, ⁵Department of Immunology and Rheumatology, Stanford University, Stanford, CA, ⁶Stanford University, Los Angeles, CA, ⁷Univ of Colorado School of Medicine/Rocky Mtn Regional Veterans Affairs Medical Center, Aurora, CO, ⁸Stanford University, Atherton, CA
Background/Purpose: Acute exposure to air pollution has been associated with flares of psoriasis and chronic inflammatory arthritides in prior studies. However, the impact of air pollution,…
Abstract Number: 2241 • ACR Convergence 2024
Associations Between Disease Activity, Physical Function and Anti-rheumatic Medications with All-cause Mortality in Rheumatoid Arthritis (RA): Data from a Canadian RA Registry
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Bindee Kuriya³, Sibel Aydin⁴, Ed Keystone⁵, Janet Pope⁶ and Claire Bombardier⁷, and OBRI investigators, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²UHN, Toronto, ON, Canada, ³University of Toronto - Toronto, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁵Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁶University of Western Ontario, London, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of hospitalizations and mortality due to RA itself, associated comorbidities, and treatment-related complications. The purpose…
Abstract Number: 2390 • ACR Convergence 2024
Anti-Sm Antibody Titers Vary During SLE Disease Course
Faye Megaris¹, Emily Wu² and Kyriakos Kirou³, ¹CUNY School of Medicine, Astoria, NY, ²Hospital for Special Surgery, Rochester, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by positive antibodies to dsDNA and/or Sm which have high specificity for the disease. While anti-dsDNA titers are…
Abstract Number: 0103 • ACR Convergence 2024
CD10highLow-Density Granulocytes Is a Potential Marker of Disease Activity in Antiphospholipid Syndrome
chun Li, Peking University People's Hospital, Beijing, China
Background/Purpose: To investigate the relationship between CD10highLow-Density Granulocytes (LDG) and disease activity in antiphospholipid syndrome(APS).Methods: This study included 99 patients with APS who were treated…
Abstract Number: 0510 • ACR Convergence 2024
Applying Machine Learning Tools for Personalized Healthcare: Predicting Responses to Biologics in Rheumatoid Patients Through Comorbidity and Blood Test Analysis
Ahmad Alsaber¹, Adeeba Alherz², Huda Khraiss³, Ghaydaa Aldabie⁴, balqees alawadhi⁵, Jiazhu Pan⁶, Adel Alawadhi⁷, KHULOUD MOHAMMED⁸, Hoda Tarakmeh⁹, Aqeel Muhanna¹⁰, Yaser Ali¹¹ and mohammad Khudadah¹², and Kuwait Registry for Rheumatic Diseases (KRRD), ¹American University of Kuwait, Kuwait, Kuwait, ²Al-Amiri Hospital, Kuwait, Kuwait, ³Monash University, Melbourne, Queensland, Australia, ⁴ministry of health kuwait, kuwait, Kuwait, ⁵The Public Authority for Applied Education and Training (PAAET), Kuwait, Al Asimah, Kuwait, ⁶University of Strathclyde, Glasgow, Scotland, United Kingdom, ⁷Kuwait University, Kuwait, Kuwait, ⁸Farwaniya Hospital, Kuwait, Kuwait, ⁹MOH Kuwait, Kuwait, Kuwait, ¹⁰Ministry of Health, Kuwait, Al Farwaniyah, Kuwait, ¹¹Mubarek Al Kabeer Hospital, Kuwait city, Kuwait, ¹²ministery of health, kuwait, Kuwait
Background/Purpose: This study aims to employ various machine learning tools to predict the responses of rheumatoid arthritis (RA) patients to biologic treatments, using data from…
Abstract Number: 0622 • ACR Convergence 2024
Translation, Adaptation and Validation of the Brazilian-Portuguese Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) Version: Partial Results from a Single Centre
Clarice Mata Machado, Cristina Lanna, Juliana Garrido, Fabiana Moura and Rosa Telles, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Background/Purpose: In recent years, several indices of disease activity in SLE have been proposed. The Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) showed a high…
Abstract Number: 0845 • ACR Convergence 2024
Weight Loss, Disease Activity, and Patient Reported Outcomes in Patients with Musculoskeletal and Autoimmune Diseases Taking Weight Loss Therapies
Thomas Riley¹, Kristin Wipfler², Katherine Wysham³, Michael George⁴, Kaleb Michaud⁵ and Joshua Baker⁴, ¹Hopsital of the University of Pennsylvania, Philadelphia, PA, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: With the popularity of medication-assisted weight loss, the current study seeks to characterize the association of weight loss, disease activity, and patient reported outcomes…
Abstract Number: 1295 • ACR Convergence 2024
A Qualitative Survey of Internal Medicine Residents’ Understanding of Appropriate ANA Testing: An 11-Year Update Since the ‘Choosing Wisely’ Campaign
Arushika Yedla¹, Wei Tang², Jaspreet Bhatti², Kyu-In Lee³ and James Miceli³, ¹Westchester Medical Center, White Plains, NY, ²Westchester Medical Center, Valhalla, ³Westchester Medical Center, Valhalla, NY
Background/Purpose: ANA testing is recommended when there is a reasonable clinical suspicion for systemic autoimmune disease. Testing in the setting of low pre-test probability, however,…
Abstract Number: 1368 • ACR Convergence 2024
Do CsDMARDs Still Play a Significant Role in Managing Rheumatoid Arthritis in the Current Biologic/JAKI Era? A Prospective Observational Study to Estimate the Extent of Response to Conventional Synthetic DMARDs in RA– Experience from a Tertiary Care Center in South India
Prabhu Vasanth¹, John Mathew² and Divya K³, ¹Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, ²Christian Medical college , Vellore , India, Vellore, India, ³Christian Medical College, Vellore, Tamil Nadu, India
Background/Purpose: Conventional synthetic DMARDs remained the mainstay of treatment of RA for decades. However, their use has decreased recently due to the emergence of biological…
Abstract Number: 1591 • ACR Convergence 2024
Domains and Outcome Measures for the Assessment of Digital Vasculopathy and Raynaud Phenomenon in Juvenile Systemic Sclerosis: A Systematic Review
Valerio maniscalco¹, Simone Appenzeller², Jennifer lemon³, Lucy stead⁴, Natalia Vasquez Canizares⁵, Gabriele Simonini⁶, Suzanne Li⁷ and Clare Pain⁸, and IJOG study, ¹Santo Stefano Hospital; Meyer Children Hospital IRCCS, Firenze, Toscana, Italy, ²Unicamp, Campinas, SP, Brazil, ³Alder Hey Children's NHS Foundation Trust, Liverpool, ⁴Liverpool University, Liverpool, ⁵Children's Hospital at Montefiore; Albert Einstein College of Medicine;, New York, NY, ⁶Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, ⁷Hackensack University Medical Center, Hackensack, ⁸Alderhey Children's NHS Foundation Trust, Liverpool, United Kingdom
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan autoimmune disease that primary affect the vascular system determining multiple organ damage and reducing quality of life…
Abstract Number: 1883 • ACR Convergence 2024
Psoriatic Arthritis Flare Incidence, Definitions and Risk Factors: A Systematic Review
Batoul Hojeij¹, Gonul Hazal Koc², Jolanda Luime¹, Marijn Vis¹, Marc R. Kok³ and Ilja Tchetverikov⁴, ¹Erasmus MC, Rotterdam, Netherlands, ²Erasmus MC, Rotterdam, Zuid-Holland, Netherlands, ³Maasstad Hospital, Rotterdam, Netherlands, ⁴Albert Schweitzer Hospital, Dordrecht, Netherlands
Background/Purpose: Combined assessment of psoriatic arthritis (PsA) flare incidence and risk factors has not been conducted before, leading to challenges in effective flare management, especially…
Abstract Number: 2246 • ACR Convergence 2024
Safety and Efficacy of Cannabidiol in Rheumatoid Arthritis Patients: A Phase 1B Pilot Randomized Placebo Controlled Trial
Veena Ranganath¹, Holly Wilhalme², Nicolette Morris³, Jenny Brook², Mihaela Taylor¹, Howard Yang¹, Tanaz Kermani⁴, Thanda Aung², Brian Skaggs¹, David Elashoff⁵ and ziva Cooper⁶, ¹UCLA, Los Angeles, CA, ²UCLA, Los Angeles, ³The University of Queensland Medical School, Ochsner Clinical School, New Orleans, LA, ⁴University of California Los Angeles, Santa Monica, CA, ⁵UCLA Department of Medicine Statistics Core, Los Angeles, ⁶UCLA Center for Cannabis and Cannabinoids, Semel Institute for Neuroscience & Human Behavior, Dept of Psychiatry and Biobehavioral Sciences, Dept of Anesthesiology and Perioperative Medicine, Los Angeles
Background/Purpose: There is no cure for rheumatoid arthritis (RA) and remission rates vary greatly 10-60%; thus, there is an unmet need for safe adjunctive therapeutic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].